You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

complete early virologic response

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Early Predict Pathological Complete Response to Neoadjuvant

Recruiting
  • Breast Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Aug 8, 2022

    Melanoma Stage IV, Melanoma Stage III, Immunetherapy Trial (nivolumab)

    Not yet recruiting
    • Melanoma Stage IV
    • +3 more
    • (no location specified)
    Dec 14, 2022

    Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

    Not yet recruiting
    • Anatomic Stage I Breast Cancer AJCC v8
    • +3 more
    • Pembrolizumab
    • +5 more
    • (no location specified)
    Apr 12, 2023

    HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • PIK3CA analysis
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Breast Cancer Trial in Ottawa (Trastuzumab)

    Recruiting
    • Breast Cancer
    • Ottawa, Ontario, Canada
      The Ottawa Hospital Cancer Centre
    Apr 26, 2022

    HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

    Recruiting
    • HER2-negative Breast Cancer
    • +5 more
    • Camrelizumab with vinorelbine and cisplatin
    • Beijing, Beijing, China
      Peking University First Hospital
    Oct 15, 2022

    About Anti-viral Regimen Adjustment on Achieving Complete

    Unknown status
    • Sustained Virologic Response
    • Hepatitis B, Chronic
    • only monitoring
    • +2 more
    • Chongqing, Chongqing, China
      The second affiliated Hospital of Chongqing Medical University
    Aug 4, 2021

    Hepatitis C Trial in Denver (Simeprivir (SMV), Sofosbuvir (SOF), Ribavirin (RBV))

    Terminated
    Has Results
    • Hepatitis C
    • Simeprivir (SMV)
    • +2 more
    • Denver, Colorado
      University of Colorado Denver (Leprino Building)
    Aug 16, 2021

    Breast Cancer Trial in United States (Positron emission tomography (PET), Trastuzumab, Pertuzumab)

    Active, not recruiting
    Has Results
    • Breast Cancer
    • Positron emission tomography (PET)
    • +2 more
    • Birmingham, Alabama
    • +9 more
    Jan 20, 2023

    Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer, Pathological Complete Response Trial in Roma (RT Dose escalation

    Recruiting
    • Neoadjuvant Chemoradiotherapy
    • +2 more
    • RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT
    • Roma, Italy
      Fondazione Policlinico Universitario A.Gemelli IRCCS
    Mar 22, 2021

    Post Analytic Treatment Interruption Study

    Recruiting
    • HIV
      • Bangkok, Thailand
        SEARCH
      Oct 19, 2022

      HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)

      Recruiting
      • HER2-positive Breast Cancer
      • Eribulin mesylate injection、Pertuzumab、Trastuzumab
      • Guanzhou, Guangdong, China
        LI YuDong
      Jul 13, 2023

      HIV Infection, Hepatitis C Infection Trial in Puerto Rico, United States (Nitazoxanide (NTZ), Pegylated interferon alfa-2a

      Completed
      Has Results
      • HIV Infection
      • Hepatitis C Infection
      • Nitazoxanide (NTZ)
      • +2 more
      • Birmingham, Alabama
      • +17 more
      Nov 2, 2021

      Immunotherapy-related CRP Kinetics in Early and Metastatic

      Recruiting
      • TNBC - Triple-Negative Breast Cancer
        • Tuebingen, Germany
          Department of Women's Health
        Jun 13, 2023

        INnovative and Micro-INvasive TEchniques for Early

        Recruiting
        • Breast Cancer
        • Liquid biopsy and imaging
        • Aviano, Pordenone, Italy
          Centro di Riferimento Oncologico
        Apr 26, 2023

        Rectal Cancer Trial in Shanghai (Total Neoadjuvant Chemoradiotherapy)

        Recruiting
        • Rectal Cancer
        • Total Neoadjuvant Chemoradiotherapy
        • Shanghai, Shanghai, China
          Fudan University Zhongshan Hospital
        Sep 28, 2022

        Study of Multidrug-Resistant Patient Outcomes With and Without

        Recruiting
        • HIV Infections
        • Multi-Antiviral Resistance
        • No ibalizumab or Pre-ibalizumab treatment
        • On ibalizumab treatment
        • Los Angeles, California
        • +38 more
        Jan 31, 2023

        HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer Trial in Belgium, France (Pertuzumab and

        Recruiting
        • HER2-positive Breast Cancer
        • +3 more
        • Pertuzumab and tratuzumab fixed dose combination
        • Trastuzumab emtansine
        • Auchenflower, Australia
        • +84 more
        Jan 16, 2023

        Breast Cancer, HER2-positive Trial in Houston (Zanidatamab, Letrozole, Tamoxifen)

        Recruiting
        • Breast Cancer
        • HER2-positive
        • Houston, Texas
          M D Anderson Cancer Center
        Jul 9, 2022

        Breast Cancer Trial in Worldwide (Perjeta, Herceptin, Docetaxel)

        Active, not recruiting
        • Breast Cancer
        • Bruxelles, Belgium
        • +55 more
        Jan 18, 2023

        Early Breast Cancer Trial in Worldwide (Trastuzumab and Pertuzumab (FDC SC) and T-DM1)

        Recruiting
        • Early Breast Cancer
        • Trastuzumab and Pertuzumab (FDC SC) and T-DM1
        • Pleven, Bulgaria
        • +55 more
        Jan 18, 2023

        Breast Cancer Trial in Dallas (Digital Mammography, Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml)

        Active, not recruiting
        • Breast Cancer
        • Digital Mammography
        • Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml
        • Dallas, Texas
          UT Southwestern Medical Center
        Jan 2, 2023

        Early Low Rectal Cancer Trial in Shanghai (PD-1 antibody, Capecitabine, Oxaliplatin)

        Recruiting
        • Early Low Rectal Cancer
        • PD-1 antibody
        • +3 more
        • Shanghai, Shanghai, China
          Fudan University Shanghai Cancer Center
        Jan 9, 2023

        Precision Neoadjuvant Triple-negative Breast Cancer Treatment

        Recruiting
        • Triple Negative Breast Cancer
        • Triple Negative Breast Neoplasms
        • Core needle biopsy
        • London, United Kingdom
          Barts Health NHS Trust
        Jun 22, 2022

        Endometrial Tumor Malignant Stage I Trial in Shanghai (Megestrol Acetate 160 MG Oral Tablet, Medroxyprogesterone Acetate 500 MG,

        Recruiting
        • Endometrial Neoplasm Malignant Stage I
        • Megestrol Acetate 160 MG Oral Tablet
        • +3 more
        • Shanghai, Shanghai, China, China
          Obstetrics and Gynecology Hospital, Fudan University
        Mar 25, 2022